JERUSALEM, January 17, 2013 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a patent-pending voice recognition technology that reduces the risks of errors during the administration of prescription medications, has signed an agreement with INTOVISION PRODUCT DEVELOPMENT & DESIGN to manufacturers the world's first voice recognition drug safety application Prototype.
The development is expected to take 4 months at which time it will be demonstrated to the world's leading drug (and drug container) manufacturers.
A video demonstration of the product applications can be viewed at http://youtube/PEy9ygT6jaA.
SafeCode is the developer of the world's first patent-protected voice recognition technology used to confirm prescription medications prior to their administration at home or in a medical center.
Using SafeCode technology, prescription medications stored in specially designed locked containers can only be accessed and administered once the caregiver or patient correctly announces the name of the drug.
The technology ensures that the appropriate medication is being administered, as mistakes have accounted for thousands of deaths in recent years. Often, nurses, doctors or patients are not careful when giving or taking medications and much medication's packaging may look similar. SafeCode Technology prevents medication errors, and thereby reduces the risk of severe injury or accidental death.
"We are hopeful that a contract with a manufacturer will be signed in the coming weeks, enabling us to build our first product prototype," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies. "There is a large addressable market for this technology due to the thousands of deaths each year related to medication errors."
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
|SOURCE Safecode Drug Technologies Corp.|
Copyright©2012 PR Newswire.
All rights reserved